First approved CD38-targeting monoclonal antibody for multiple myeloma
See which of your patients are suitable for DARZALEX®
Prof. van de Donk discusses the multiple mechanisms of action of DARZALEX®
In this video, Prof. Niels van de Donk of VU University Medical Center, Amsterdam, briefly discusses the multiple mechanisms of action of DARZALEX® and how the drug promotes myeloma and immunosuppressor cell death, leading to durable anti-tumour responses
A powerful mechanism of action
View an animation that demonstrates the multifaceted mode of action of DARZALEX® – the first approved CD38-targeting monoclonal antibody for MM
MM: multiple myeloma
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Darzalex®, veja aqui
